Shop
Your Account Sign In
Support Us
Subscribe
Britain World Editorial Features Culture Sport
Britain World Editorial Features Culture Sport
Climate Crisis Far Right Gaza Workers' Rights Labour Party Morning Star Video
Latest editorial
Hypocritical US ‘free speech’ concerns are an opportunity for the left to reclaim that vital cause
Advertise Contact us Shop Subscribe Support us Daily Alert
Climate Crisis Far Right Gaza Workers' Rights Labour Party Morning Star Video
Gifts from The Morning Star
Britain / 21 July 2022
Flynn and Pfizer fined £70m for overcharging NHS for epilepsy drugs
Michael Selby-Green
Recent
Palestinians carry the body of Al Jazeera correspondent Anas al-Sharif at his funeral outside Gaza City's Shifa hospital complex, August 11, 2025
British Foreign Policy / 14 August 2025
Gazans in Britain call on government for action on journalists' killings
14 August 2025
Monarchy / 14 August 2025
Free King Charles portrait rejected by 46,000 public institutions
14 August 2025
Arms Trade / 14 August 2025
Rolls-Royce making fortune from ‘untested new nuclear market’
14 August 2025

Campaign for Nuclear Disarmament condemns the firm's plans for AI-assisted small modular reactors

Scotland / 14 August 2025
Anti-genocide protesters greet US Vice-president JD Vance in Ayrshire
14 August 2025
Housing Crisis / 14 August 2025
No-fault evictions by bailiffs up in Labour's first year
14 August 2025
Education / 14 August 2025
NEU warns against ‘one size fits all’ exams system on A-level results day
14 August 2025
Cost-of Living Crisis / 14 August 2025
Students at ‘breaking point’ as half of undergraduates say financial worries hurts their mental health
14 August 2025
Book your advertising in print and online
Morning Star Shop

PHARMACEUTICAL companies Flynn and Pfizer have been fined nearly £70 million after they overcharged the NHS for a life-saving epilepsy drug, the Competition and Markets Authority (CMA) announced today.

The body said that the two drug companies had illegally “abused their dominant positions” in the market to charge unfairly high prices over four years.

Costs to the NHS for the phenytoin sodium drug increased from £2m in 2012 to £50m in 2013.

The 95th Anniversary Appeal
Support the Morning Star
You have reached the free limit.
Subscribe to continue reading.
Become a subscriber
More from this author
Minister without Portfolio Nadhim Zahawi arrives in Downing
Britain / 15 January 2023
Former chancellor Zahawi agrees to pay millions in tax following questions over his finances
15 January 2023
Britain / 13 January 2023
Scottish Greens call on Westminster to ‘wake up to the reality of the climate crisis’
13 January 2023
Britain / 13 January 2023
Cost of dying soars by 3.8 percent
13 January 2023
A child’s shoe and clothes are left at a site of Saudi-led
Britain / 10 January 2023
British arms have contributed to ‘pattern of violence against civilians’ in Yemen, Oxfam report finds
10 January 2023
Similar stories
A general view of staff on a NHS hospital ward at Ealing Hos
Britain / 4 March 2025
Energy costs are crippling the NHS
4 March 2025
More than seven in 10 health workers says patients struggling with their bills — a public health crisis ‘that is entirely preventable’
Billionaires: Facebook CEO Mark Zuckerberg, Amazon CEO Jeff
Features / 25 January 2025
Labour’s servitude to big tech will not end well
25 January 2025
The government needs to raise its game when it comes to the tech giants who behave like the robber barons of old, argues NICK MATTHEWS
GETTING THE PULSE? Keir Starmer, and Health Secretary Wes St
Features / 25 October 2024
The NHS - A manifesto for renewal
25 October 2024
FAWZI IBRAHIM argues that the NHS needs reforms to bring it back to its original tenets and outlines five fundamental changes that are critical to achieving this
An electron micrograph of HIV-1 virus particles (colourized
Features / 13 September 2024
Public pharma v abusive prices: the case of the latest HIV-prevention drug
13 September 2024
ALAN ROSSI SILVA argues that Gilead’s HIV prevention drug, while promising, highlights systemic failures in the pharmaceutical industry, showing the need to shift towards state-owned drug development and production